Evidence map›Paper›PMID 29512295›Full record

ReviewCNS neuroscience & therapeutics2018

Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.

Sandra M Holley, Talia Kamdjou, Jack C Reidling, Brian Fury, Dane Coleal-Bergum, Gerhard Bauer, Leslie M Thompson, Michael S Levine, Carlos Cepeda

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington's disease mice and innervate the striatum.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  3. Article
  4. Review
  5. Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2022
    Article
  6. Review
  7. New Avenues for the Treatment of Huntington's Disease.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Huntington's disease: From basic science to therapeutics.CNS neuroscience & therapeutics · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandra M HolleyIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID 0000-0002-2643-4961
Talia KamdjouIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Jack C ReidlingInstitute for Memory Impairment and Neurological Disorders, University of California, Irvine, CA, USA.
Brian FuryInstitute for Regenerative Cures, University of California, Davis, Sacramento, CA, USA.
Dane Coleal-BergumInstitute for Regenerative Cures, University of California, Davis, Sacramento, CA, USA.
Gerhard BauerInstitute for Regenerative Cures, University of California, Davis, Sacramento, CA, USA.
Leslie M ThompsonInstitute for Memory Impairment and Neurological Disorders, University of California, Irvine, CA, USA.
Michael S LevineIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Carlos CepedaIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID 0000-0001-5953-6692

Funding

UCLA Center for Translational Research in Neurodevelopment: UC-TRaNU54HD087101 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCRACKEN, JAMES T. · 2016 to 2020
$6.5M
NICHD NIH HHS U54 HD087101
6 · The paper itself

Abstract

The principal symptoms of Huntington's disease (HD), chorea, cognitive deficits, and psychiatric symptoms are associated with the massive loss of striatal and cortical projection neurons. As current drug therapies only partially alleviate symptoms, finding alternative treatments has become peremptory. Cell replacement using stem cells is a rapidly expanding field that offers such an alternative. In this review, we examine recent studies that use mesenchymal cells, as well as pluripotent, cell-derived products in animal models of HD. Additionally, we provide further electrophysiological characterization of a human neural stem cell line, ESI-017, which has already demonstrated disease-modifying properties in two mouse models of HD. Overall, the field of regenerative medicine represents a viable and promising avenue for the treatment of neurodegenerative disorders including HD.

Indexed as

Stem Cell TransplantationAnimalsDisease Models, AnimalHumansHuntington DiseaseRodentiaanimal modelselectrophysiologyHuntington's diseasestem cells

Identifiers

PMID29512295
PMCPMC6489814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.